Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ

Thrombosis and Haemostasis

Volumn 85, Issue 1, 2001, Pages 93-100

  Sandberg, H ^a   Almstedt, A ^a   Brandt, J ^a   Gray, E ^a   Holmquist, L ^a   Oswaldsson, U ^a   Sebring, S ^a   Mikaelsson, M ^a  

^a Envirotainer Engineering AB   (Sweden)

Author keywords

B domain deletion; Factor VIII; Function; Recombinant; Structure

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9A; CALCIUM; PHOSPHOLIPID; PROTEIN S; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; VON WILLEBRAND FACTOR;

ARTICLE; ASSOCIATION; BINDING AFFINITY; CONTROLLED STUDY; DISSOCIATION CONSTANT; FUNCTIONAL ASSESSMENT; HEMOSTASIS; HUMAN; HUMAN CELL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; STRUCTURE ANALYSIS; TRANSLATION REGULATION;

EID: 0035159198     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1612910     Document Type: Article

References (33)

1. Structure of human factor VIII
2. Molecular cloning of a cDNA encoding human antihaemophilic factor
3. Isolation and characerization of human factor VIII: Molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma
4. Synthesis, processing, and secretion of recombinant human factor VIII
5. Purified human factor VIII procoagulant protein: Comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs
6. Novel forms of B-domain-deleted recombinant factor VIII molecules, Construction and biochemical characterization
7. Structural and functional characterization of factor VIII-delta II, a new recombinant factor VIII lacking most of the B-domain
8. Biochemical, immunological, and in vivo functional characterization of B-domain deleted factor VIII
9. A large region (c.95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity
10. Calculation of protein conformation from circular dichroism
11. The simplified two-stage assay for factor VIII
12. Methodology of the one-stage assay of factor VIII (VIII:C)
13. An improved procedure for accurate assay of factor VIII
14. 740: Discordant in vitro and in vivo activity
15. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system
16. Glycosylation pattern of a B-domain-deleted recombinant factor VIII molecule (r-VIII SQ)
17. Influence of phospholipids on the assessment of factor VIII activity
18. The importance of activation of antihemophilic globulin, and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity
19. The size of human factor VIII heterodimers and the effects produced by thrombin
20. The control of hemostasis: Protein C and Protein S
21. 1684 of Factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor
22. The interaction between human blood-coagulation factor VIII and von Willebrand factor
23. A role for the C2 domain of factor VIII in binding to von Willebrand factor
24. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine
25. The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets
26. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor
27. Purification of human factor VIII: C and its characterization by western blotting using monoclonal antibodies
28. Human factor VIII: Purification from commercial factor VIII concentrate, characterization, identification and radiolabeling
29. Von Willebrand factor as a regulator of intrinsic factor X activation
30. Isolation and characterization of lipid-protein particles containing platelet factor 3 released from human platelets
31. The binding kinetics of B-domain-deleted recombinant factor VIII and plasma-derived factor VIII to phospholipid vesicles
32. Second generation, B-domain deleted recombinant factor VIII
33. Amino acid residues 721-729 are required for full factor VIII activity